Cyrus Buckman

Cyrus Buckman

Auto-generated profile, based on publicly available information

Cyrus Buckman

Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford Health Care, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Clinical and Experimental Gastroenterology
Verified
Journal Article
Open access
PDF file
JGJohn Gubatan
John Gubatan
KKKian Keyashian
Kian Keyashian
SRSamuel J. S. Rubin
Samuel J. S. Rubin
JWJenny Wang
Jenny Wang
CBCyrus Buckman
Cyrus Buckman
SSSidhartha Sinha
Sidhartha Sinha
Leukocyte trafficking to the gastrointestinal tract is recognized to play a role in the pathogenesis of inflammatory bowel disease (IBD). Integrins are expressed on immune cells and interact with cell adhesion molecules (CAM) to mediate leukocyte trafficking. Blockade of the gut-tropic integrin α 4β 7 and its subunits has been exploited as a therapeutic target in IBD. Natalizumab (anti-α 4) is approved for moderate to severe Crohn’s disease (CD), but its use is limited due to potential risk of progressive multifocal leukoencephalopathy. Vedolizumab (anti-α 4β 7) is approved for the treatment of ulcerative colitis (UC) and CD. It is the most widely used anti-integrin therapy in IBD and has been shown to be effective in both induction and maintenance therapy, with a favorable safety profile. Several models incorporating clinical, genetic, immune, gut microbial, and vitamin D markers to predict response to vedolizumab in IBD have been developed. Etrolizumab (anti-β 7) blocks leukocyte trafficking via α 4β 7 and cell adhesion via αEβ 7 integrins. Large phase 3 clinical trials evaluating efficacy of etrolizumab in the induction and maintenance of patients with IBD are underway. Other investigational anti-integrin therapies include abrilumab (anti-α 4β 7 IgG2), PN-943 (orally administered and gut-restricted α 4β 7 antagonist peptide), AJM300 (orally active small molecule inhibitor of α 4), and ontamalimab (anti-MAdCAM-1 IgG).

25 January 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
JBJanos Barrera
Janos Barrera
DLDevi Lakhlani
Devi Lakhlani
SFShannon Francis
Shannon Francis
BMBhagvat Maheta
Bhagvat Maheta
CGCayo Gonzalez
Cayo Gonzalez
RNRahim Nazerali
Rahim Nazerali